Ahzantive (aflibercept-mrbb) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with wet age-related macular degeneration (AMD), an eye disease that can cause vision loss.
Ahzantive is a medicine that blocks proteins called vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF). These proteins can cause abnormal blood vessels to grow and leak fluid in the eye. By blocking these proteins, Ahzantive helps reduce abnormal blood vessel growth and fluid leakage.
Ahzantive is a biosimilar of Eylea. This means it is made from living cells and is designed to work like the original medicine. The FDA requires biosimilars to have no meaningful differences in safety or how well they work.
Doctors prescribe Ahzantive when a person has wet (neovascular) age-related macular degeneration (AMD), an eye disease that can cause vision loss.
Ahzantive is given as an injection into the eye by a qualified doctor. The treatment schedule depends on the person’s needs.
The recommended starting dose of Ahzantive is 2 milligrams (0.05 milliliters of a solution containing 40 milligrams per milliliter), injected into the eye every four weeks for the first three months.
After the first three months, the recommended dose is 2 milligrams once every eight weeks.
Some people may need injections every four weeks after the first three months.
After one year of effective treatment, some people may receive injections every 12 weeks. However, this schedule is not as effective as the recommended every-eight-week schedule.
Your doctor will check your eyes regularly and decide which treatment schedule is appropriate for you.
This information is based on prescribing information, but your healthcare provider may tailor your treatment plan. Always follow their guidance.
In clinical studies of aflibercept, the most common side effects occurred in about 5 percent to 27 percent of people with wet AMD. These include:
Ahzantive can cause serious side effects that may require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
If you experience serious side effects, you can report them to the FDA online or by calling 1-800-FDA-1088. You can also contact the drug's manufacturer.
Valorum Biologics, the manufacturer of Ahzantive, offers the ValorumPRO program. Eligible people may qualify for $0 copay assistance and deductible support, including administration-specific copay assistance. A Patient Assistance Program (PAP) may also provide the medication at no cost to eligible people.
The ValorumPRO program also helps providers streamline administrative processes, navigate reimbursement, identify affordability options, and support continuity of care throughout the treatment journey.
To learn more, visit ValorumPRO or call 844-825-6786.
Before receiving Ahzantive, tell your doctor if you:
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Do not receive Ahzantive if you have:
You may have temporary vision changes after an Ahzantive injection or related eye examinations. Do not drive or use machinery until your vision has recovered enough to do so safely.
Ahzantive is also FDA-approved to treat:
If you are pregnant or planning to become pregnant, talk to your doctor before receiving Ahzantive. It is not known whether Ahzantive can harm a fetus in humans.
Ahzantive should be used during pregnancy only if the possible benefits outweigh the potential risks.
Females who can become pregnant should use effective birth control before starting Ahzantive, during treatment, and for at least three months after their last injection.
Ahzantive is not recommended during breastfeeding.
These answers are fact-checked by our editorial staff.
How effective is Ahzantive for wet AMD?
In two clinical studies of people with wet age-related macular degeneration (wet AMD), 94 percent to 95 percent of people treated with 2 milligrams of aflibercept, the active medicine in Ahzantive, maintained their vision after 52 weeks. This means they lost fewer than 15 letters on a standard eye chart.
These results were similar to those seen with ranibizumab, another eye medicine. In the ranibizumab groups, 94 percent to 95 percent of people maintained their vision.
The studies tested different dosing schedules for aflibercept, including injections every four weeks and injections every eight weeks after three monthly starting doses.
How long does Ahzantive take to work for wet AMD?
Clinical studies of aflibercept measured vision outcomes at different times, including at week 52. However, the studies do not say exactly how soon people may notice an improvement in their vision.
The recommended Ahzantive dosing schedule starts with injections every four weeks for the first three months, followed by one injection every eight weeks.
What tests or monitoring are needed with Ahzantive for AMD?
Right after each Ahzantive injection, your doctor will check for increased pressure inside your eye. This may include measuring eye pressure or checking blood flow to the optic nerve, which carries signals from your eye to your brain.
Your doctor will also check your eyes regularly during treatment to see how well the medicine is working.
If you develop eye pain, redness, sensitivity to light, or changes in vision after an injection, seek immediate care from an eye doctor. These may be signs of serious eye problems, such as an eye infection, retinal detachment, or inflammation of blood vessels in the retina.
On myAMDteam, people share their experiences with age-related macular degeneration, get advice, and find support from others who understand.
Learn more about Ahzantive and age-related macular degeneration care:
Become a member to get even more